Clinical trialPhase 1Recruiting
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
A Phase 1 Dose-Finding and Dose-Expansion Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
- Outcome
- Ongoing
- Phase
- Phase 1
- Status
- Recruiting
- Study type
- Interventional
- Start
- 13 November 2025
- Expected end
- 31 March 2030
- Enrollment
- 76 participants
- Sites
- 7
- Primary outcomes
- Part A (Dose Finding): To determine the Maximum Tolerated Dose (MTD); Number of participants with treatment related adverse events as assessed by CTCAE version 5.0; To evaluate safety and tolerability of KIVU-107
- Sponsor type
- Industry
- Results posted
- No
- Last update
- 24 September 2026
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of KIVU-107, a PTK7-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid tumors.
Detailed description public domain (ClinicalTrials.gov)
Part A: The primary objective of Part A of this study is to evaluate the safety and tolerability of KIVU-107 and to determine the maximum tolerated dose (MTD)/Recommended Dose for Expansion (RDE). Part B: The primary objective of Part B of this study is to confirm the safety and tolerability of KIVU-107 at the RDE.